Stock vs Stock Comparison

Can-Fite BioPharma Ltd. vs Agilent Technologies, Inc.

A wins the Tale of the Tape 8–1.

CANF
A$137.40

🏆 Tale of the Tape

18
CANFA
-2426.7%Profitability (Net Margin)18.8%
Valuation (P/E)27.3x
-115.9%Efficiency (ROIC)11.8%
2/9Health (Piotroski F)5/9
Safety (Altman Z)4.6
-39.9%Growth (Rev YoY)6.7%
Risk (Sharpe 1Y)0.32
0.70xBalance Sheet (D/E)0.89x
FCF Yield3.41%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Fundamentals

MetricCANFA
Market Cap$38.2B
P/E Ratio27.3x
Forward P/E20.5x
P/B5.37x
Dividend Yield0.75%
Beta1.22

Quantitative Metrics

MetricCANFA
DCF Fair Value$50.34
DCF Upside-57.1%
Piotroski F2/95/9
Altman Z4.57
Beneish M-2.46
FCF Yield3.41%
Net Debt/EBITDA0.7x
ROIC-115.9%11.8%
WACC12.1%
ROIC – WACC-0.3pp
Gross Margin52.4%
Net Margin-2426.7%18.8%
Rev Growth YoY-39.9%6.7%
Sharpe (1Y)0.32
Max Drawdown 3Y
FCF Payout Ratio24%

CANF Price

Loading chart...

A Price

Loading chart...

ETF Exposure

CANF found in:

EWX0.07%
SPEM0.01%

A found in:

MOAT1.31%
VOT0.77%
XLV0.61%
VHT0.53%
VO0.33%
ONEV0.29%
RSP0.18%
VIG0.15%
VTV0.13%
SCHV0.12%
SPYV0.11%
IWD0.11%
VONV0.10%
ONEO0.09%
ESGV0.07%
QUS0.07%
SPLG0.07%
IVV0.07%
ITOT0.06%
SCHX0.06%
SCHB0.05%
SPY0.05%
VTI0.05%
VOO0.05%
VONE0.05%
SPTM0.05%
URTH0.04%
ACWI0.04%
DGRW0.04%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

CANF vs A: Head-to-Head Analysis

Can-Fite BioPharma Ltd. (CANF) and Agilent Technologies, Inc. (A) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, A leads 8–1 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, CANF generates a return on invested capital (ROIC) of -115.9% compared to A's 11.8%. This suggests A is more effective at deploying capital to generate shareholder returns.

CANF appears in 2 ETFs tracked by SecuritiesDB, while A appears in 29 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, CANF or A?

Our quantitative analysis compares CANF and A across nine fundamental dimensions. A wins the Tale of the Tape 8–1. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are CANF and A correlated?

Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.